腹膜透析患者使用胃酸抑制剂的腹膜炎与死亡风险
该研究采用目标试验模拟方法,基于香港电子健康记录(2006-2019)分析11,693例腹膜透析患者。结果显示,启动质子泵抑制剂(PPI)与腹膜炎(HR 1.53)、全因死亡(HR 1.55)及腹膜炎相关死亡(HR 1.39)风险升高相关;H2受体拮抗剂(H2RA)亦与腹膜炎(HR 1.21)和全因死亡(HR 1.13)风险升高相关。头对头分析中PPI较H2RA全因死亡风险更高(HR 1.38)。
要点
- 腹膜透析患者启动PPI或H2RA均与腹膜炎及死亡风险增加相关。
- PPI较H2RA与更高的全因死亡和腹膜炎相关死亡风险相关。
- 基线风险较高的患者中,胃酸抑制剂的风险升高更明显。
核心结论
- 腹膜透析患者启动胃酸抑制剂较未启动者腹膜炎和死亡风险增加,且PPI较H2RA死亡风险更高。
研究设计与样本
- 目标试验模拟研究,使用香港电子健康记录(2006-2019),采用168个月序贯设计、逆概率治疗加权和离散风险回归。
- 共纳入11,693例个体,240,431人-试验,比较PPI启动者、H2RA启动者和未启动者。
主要发现
- PPI启动vs未启动:腹膜炎HR 1.53(95%CI 1.31-1.80),全因死亡HR 1.55(95%CI 1.43-1.67),腹膜炎相关死亡HR 1.39(95%CI 1.05-1.58)。
- H2RA使用:腹膜炎HR 1.21(95%CI 1.08-1.35),全因死亡HR 1.13(95%CI 1.06-1.20)。
- PPI vs H2RA头对头:腹膜炎风险无显著增加,全因死亡HR 1.38(95%CI 1.23-1.54),腹膜炎相关死亡HR 1.85(95%CI 1.07-3.19)。
- 异质性分析显示基线风险较高者风险升高更明显。
临床怎么用
- 腹膜透析患者应谨慎使用胃酸抑制治疗,尤其PPI。
- 对高基线风险患者,处方胃酸抑制剂时需更严密监测腹膜炎和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peritonitis is a critical complication in patients undergoing peritoneal dialysis (PD). The association between gastric acid suppressants (GAS), specifically proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), and peritonitis risk remains controversial, with conflicting evidence regarding their safety. METHODS: We conducted a target trial emulation using Hong Kong electronic health records (2006-2019), applying a 168-month sequential design to minimize immortal time bias. Using inverse probability of treatment weighting and discrete hazards regression, we estimated hazard ratios (HRs) for peritonitis, all-cause mortality, and peritonitis-related mortality among PPI initiators, H2RA initiators, and non-initiators (95% confidence interval [CI] calculated using 500-resample bootstrapping). We also performed a PPI versus H2RA head-to-head comparison and predictive approaches to treatment effect heterogeneity analysis. RESULTS: Among 11,693 individuals (240,431 person-trials), PPI initiation (vs. non-initiation) was associated with higher risks of peritonitis (HR 1.53, 95% CI 1.31-1.80), all-cause mortality (HR 1.55, 95% CI 1.43-1.67), and peritonitis-related mortality (HR 1.39, 95% CI 1.05-1.58). H2RA use was also associated with increased risk of peritonitis (HR 1.21, 95% CI 1.08-1.35) and all-cause mortality risks (HR 1.13, 95% CI 1.06-1.20). Head-to-head analysis showed no significant increase in peritonitis risk with PPIs versus H2RAs, but revealed an association between PPI use and higher all-cause mortality (HR 1.38, 95% CI 1.23-1.54) and peritonitis-related mortality (HR 1.85, 95% CI 1.07-3.19). Predictive approaches to treatment effect heterogeneity analysis indicated that risk elevations were more pronounced in individuals with higher baseline risk. CONCLUSIONS: In patients on PD, GAS initiation is associated with increased peritonitis and mortality compared with non-initiation. Furthermore, PPIs were associated with higher mortality risks than H2RAs. These findings highlight the need for cautious use of acid-suppressive therapy.
引用
- Fan M, Man KKC, Li X, et al. Peritonitis and Mortality Risks of Gastric Acid Suppressants in Patients Undergoing Peritoneal Dialysis. Kidney Int Rep. 2026. PMID: 42668645. doi:10.1016/j.ekir.2026.106991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。